Journal Information (Dr. Peixin Dong, MD, PhD)
Aims:
Cancer Immuno Perspectives (CIP) stands as an international journal that provides state-of-the-art, authoritative review articles at the intersection of cancer immunology and immunotherapy. Our core mission is to provide clinicians and researchers with the most up-to-date knowledge in cancer immune research and therapeutic advancements. CIP is dedicated to curating a collection of high-impact manuscripts that demonstrate the synergy of integrating oncology research with other fields, fostering novel diagnostic methods and therapeutic strategies for human cancers. We seek contributions that are not only at the forefront of their respective fields but also offer fresh insights and methodologies to the cancer-immune community.
Scope:
Our journal has a particular interest in topics such as endogenous anti-tumor immunity, the role of inflammation in tumor promotion, the significance of cancer antigens, and the development of vaccines and antibodies. We also focus on cellular therapy, cytokines, immune regulation, immune suppression, and the immunomodulatory effects of cancer treatment. To broaden and deepen our scope, we are expanding our focus to include the following rapidly growing and innovative fields in cancer immunology and immunotherapy. The scope of CIP encompasses a wide range of topics, including but not limited to:
l Endogenous Anti-Tumor Immunity: We examine the innate and adaptive immune responses that spontaneously counteract neoplastic growth, revealing the underlying mechanisms of tumor regression and resistance to cancer.
l Inflammation and Tumor Promotion: Our focus is on the intricate relationship between inflammation and cancer development, illuminating how chronic inflammation fosters oncogenic transformation and drives tumorigenesis.
l Cancer Antigens: We lead the discovery and detailed characterization of tumor-specific antigens, essential for developing precise immunotherapies that enable the immune system to identify and eliminate cancer cells.
l Vaccines and Antibodies: We are committed to advancing the development and application of cancer vaccines and monoclonal antibodies, with an emphasis on strategies that enhance antigen presentation, boost immune recognition, and precisely target tumors.
l Cellular Therapy: We utilize T cells and NK cells in adoptive immunotherapies, exploring the potential of chimeric antigen receptor (CAR) modifications and genetic engineering to boost the effectiveness of cell-based cancer treatments.
l Cytokines: We analyze the diverse roles of cytokines in shaping the cancer immunity landscape, from their ability to strengthen immune responses to their complex influence on tumor development.
l Immune Regulation: We chart the balance between immune activation and suppression in cancer, concentrating on the molecular interactions that dictate immune response outcomes and therapeutic opportunities.
l Immune Suppression: We scrutinize the strategies by which tumors evade immune detection, including the exploitation of immune checkpoints and the alteration of immune cell function, assessing the impact on immunotherapeutic approaches.
l Immunomodulatory Effects of Cancer Treatment: We assess the profound effects of conventional cancer therapies on the immune system, exploring potential synergies with immunotherapies and the potential for abscopal effects.
l Cancer Immunotherapy Combinations: We explore the potential of combining different immunotherapies to enhance antitumor immunity, surpassing the effects of single-agent treatments.
l Oncolytic Virus Therapy: We investigate the development and application of oncolytic viruses, designed to precisely target and destroy cancer cells while stimulating the immune system's quiescent responses. Our goal is to understand the full range of their mechanisms and therapeutic potential in the battle against cancer.
By covering these areas, CIP aims to offer a comprehensive platform for disseminating the latest research and advancements in cancer immunology and immunotherapy, fostering the exchange of knowledge and the development of novel therapeutic strategies.
Article Types:
l CIP publishes outstanding review articles and original articles reporting significant advances that span the discipline of cancer immunology, from basic investigations of host-tumor interactions to developmental therapeutics in model systems, and early translational studies in patients.
l The journal also publishes opinion pieces of broad significance across the spectrum of cancer immunology research.
Priority in CIP:
l At CIP, we prioritize publications that not only enhance our understanding of the foundational mechanisms of cancer immunity but also hold the promise of propelling the development of effective immunotherapies.
l We recognize the burgeoning interdisciplinary nature of cancer research and actively encourage submissions that exemplify the convergence of oncology with computer science, materials science, physics, and mathematics. These integrative approaches are pivotal for transforming our insights into the molecular underpinnings of cancer immunity, thereby driving innovative advancements in diagnostic techniques and therapeutic strategies.
Commitment to Fast and Fair Reviews:
l We are dedicated to ensuring a fair and expedited review process. Upon receipt, each submission undergoes a thorough initial assessment to ensure it meets our journal's criteria. We strive to deliver the first decision—whether it be a rejection or a request for revision—within a prompt five-business-day timeframe. For manuscripts that proceed to the peer-review stage, we anticipate our expert reviewers to provide their detailed recommendations, ranging from outright rejection to major or minor revisions, within a targeted 14-business-day window. This streamlined approach ensures both expedience and thoroughness in our evaluation process. Decisions on peer-review are typically made within two business days, with publication decisions following promptly after reviewer reports are received.
l Furthermore, we are dedicated to ensuring that the peer-review process is not only swift but also equitable. We are committed to upholding the integrity of the process by ensuring that each submission is judged on its scientific merit and contribution to the field.
Benefits to Authors:
CIP now offers all authors free complimentary language editing services, ensuring that their manuscripts adhere to the highest academic language standards. Our Standard, Rapid, and Academic services include premium language editing by native English-speaking experts, ensuring that papers are clearly and precisely articulated in English prior to submission.
Publishing Model and Copyright:
Our journal employs an immediate gold open access (OA) publication option. Authors maintain copyright ownership of their scholarly contributions. We have adopted the Creative Commons Attribution license (https://creativecommons.org/licenses/by/4.0/), which facilitates broad dissemination by permitting users to freely disseminate, transform, and expand upon the content across various mediums and formats, always provided that proper credit is attributed to the original creator. This license also encompasses the flexibility for commercial applications.
Article Processing Charge:
We are waiving the article processing charge (APC), which is usually applicable for all the articles received in 2025. Please note that waiving the APC does not affect editorial decision-making.